Literature DB >> 28984290

Role of autophagy in oncolytic herpes simplex virus type 1-induced cell death in squamous cell carcinoma cells.

Y Furukawa1, A Takasu1, Y Yura1.   

Abstract

Herpes simplex virus type 1 (HSV-1) is one of the most widely studied viruses for oncolytic virotherapy. In squamous cell carcinoma (SCC) cells, the role of autophagy induced by neurovirulence gene-deficient HSV-1s in programmed cell death has not yet been elucidated. The oncolytic HSV-1 strain RH2, which lacks the γ34.5 gene and induces the fusion of human SCC cells, was used. RH2 replicated and induced cell death in SCC cells. RH2 infection was accompanied by the aggregation of microtubule-associated protein 1 light chain 3 (LC3) in the cytoplasm, the conversion of LC3-I to LC3-II and the formation of double-membrane vacuoles containing cell contents. No significant changes were observed in the expression of Bcl-2 or Bax, while a slight decrease was observed in that of Beclin 1. The autophagy inhibitors, 3-methyladenine (3-MA) and bafilomycin A1, did not affect viral replication, but significantly inhibited the cytotoxicity of RH2. The caspase-3 inhibitor z-DEVD-fmk and caspase-1 inhibitor z-YVAD-fmk also reduced the cytotoxicity of RH2. These results demonstrated that γ34.5 gene-deficient HSV-1 RH2 induced autophagic cell death in SCC cells as well as pyroptosis and apoptosis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28984290     DOI: 10.1038/cgt.2017.33

Source DB:  PubMed          Journal:  Cancer Gene Ther        ISSN: 0929-1903            Impact factor:   5.987


  52 in total

1.  Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1.

Authors:  Kerrington D Smith; James J Mezhir; Kai Bickenbach; Jula Veerapong; Jean Charron; Mitchell C Posner; Bernard Roizman; Ralph R Weichselbaum
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 2.  Oncolytic viruses: From bench to bedside with a focus on safety.

Authors:  Pascal R A Buijs; Judith H E Verhagen; Casper H J van Eijck; Bernadette G van den Hoogen
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

3.  Effect of γ34.5 deletions on oncolytic herpes simplex virus activity in brain tumors.

Authors:  Ryuichi Kanai; Cecile Zaupa; Donatella Sgubin; Slawomir J Antoszczyk; Robert L Martuza; Hiroaki Wakimoto; Samuel D Rabkin
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

4.  Methods in mammalian autophagy research.

Authors:  Noboru Mizushima; Tamotsu Yoshimori; Beth Levine
Journal:  Cell       Date:  2010-02-05       Impact factor: 41.582

5.  Immunogenic cell death by oncolytic herpes simplex virus type 1 in squamous cell carcinoma cells.

Authors:  A Takasu; A Masui; M Hamada; T Imai; S Iwai; Y Yura
Journal:  Cancer Gene Ther       Date:  2016-03-18       Impact factor: 5.987

Review 6.  Rethinking herpes simplex virus: the way to oncolytic agents.

Authors:  Gabriella Campadelli-Fiume; Carla De Giovanni; Valentina Gatta; Patrizia Nanni; Pier-Luigi Lollini; Laura Menotti
Journal:  Rev Med Virol       Date:  2011-05-27       Impact factor: 6.989

7.  The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase.

Authors:  B He; M Gross; B Roizman
Journal:  Proc Natl Acad Sci U S A       Date:  1997-02-04       Impact factor: 11.205

8.  Cell type-dependent requirement of autophagy in HSV-1 antiviral defense.

Authors:  Brian Yordy; Akiko Iwasaki
Journal:  Autophagy       Date:  2012-10-24       Impact factor: 16.016

9.  A novel fusogenic herpes simplex virus for oncolytic virotherapy of squamous cell carcinoma.

Authors:  Hiroo Takaoka; Gen Takahashi; Fumi Ogawa; Tomoaki Imai; Soichi Iwai; Yoshiaki Yura
Journal:  Virol J       Date:  2011-06-10       Impact factor: 4.099

Review 10.  Innate and adaptive immunity through autophagy.

Authors:  Dorothee Schmid; Christian Münz
Journal:  Immunity       Date:  2007-07       Impact factor: 31.745

View more
  7 in total

1.  Proteomic Analysis of Secretomes of Oncolytic Herpes Simplex Virus-Infected Squamous Cell Carcinoma Cells.

Authors:  Shinya Tada; Masakazu Hamada; Yoshiaki Yura
Journal:  Cancers (Basel)       Date:  2018-01-23       Impact factor: 6.639

Review 2.  Oncolytic viruses: how "lytic" must they be for therapeutic efficacy?

Authors:  Maria Eugenia Davola; Karen Louise Mossman
Journal:  Oncoimmunology       Date:  2019-03-28       Impact factor: 8.110

Review 3.  Oncolytic Viruses: Newest Frontier for Cancer Immunotherapy.

Authors:  Masmudur M Rahman; Grant McFadden
Journal:  Cancers (Basel)       Date:  2021-10-29       Impact factor: 6.639

Review 4.  Autophagy in Tumor Immunity and Viral-Based Immunotherapeutic Approaches in Cancer.

Authors:  Ali Zahedi-Amiri; Kyle Malone; Shawn T Beug; Tommy Alain; Behzad Yeganeh
Journal:  Cells       Date:  2021-10-06       Impact factor: 7.666

Review 5.  Herpes Simplex Virus: A Versatile Tool for Insights Into Evolution, Gene Delivery, and Tumor Immunotherapy.

Authors:  Prapti H Mody; Sushila Pathak; Laura K Hanson; Juliet V Spencer
Journal:  Virology (Auckl)       Date:  2020-05-29

Review 6.  Efficient Delivery and Replication of Oncolytic Virus for Successful Treatment of Head and Neck Cancer.

Authors:  Masakazu Hamada; Yoshiaki Yura
Journal:  Int J Mol Sci       Date:  2020-09-25       Impact factor: 5.923

Review 7.  Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions.

Authors:  Si-Yuan Lu; Jie Hua; Jin Xu; Miao-Yan Wei; Chen Liang; Qing-Cai Meng; Jiang Liu; Bo Zhang; Wei Wang; Xian-Jun Yu; Si Shi
Journal:  Int J Biol Sci       Date:  2021-06-26       Impact factor: 6.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.